Ketamine Care for the Depressive Phase
of Bipolar I & II
Evidence-Based Support for New Mothers Who Need More
The Burden of Bipolar Depression
Bipolar depression is one of the most challenging and undertreated conditions in psychiatry. Emerging evidence suggests ketamine can provide rapid depressive relief — with close monitoring and careful coordination with your psychiatric team.
Bipolar disorder is defined by alternating episodes of mania or hypomania and depression — yet patients spend the vast majority of their time in the depressive phase. Studies tracking bipolar disorder over years find that individuals are symptomatic with depression roughly three times more often than with elevated mood states, and the depressive phase accounts for most of the functional impairment, disability, and elevated suicide risk associated with the illness.
Treating bipolar depression is genuinely difficult. Standard antidepressants, when used without adequate mood stabilization, carry a risk of triggering a “manic switch” — potentially precipitating a hypomanic or manic episode. This has historically led to cautious, often inadequate treatment. Mood stabilizers like lithium and lamotrigine provide partial protection but frequently leave significant depressive symptoms unaddressed. Many patients with treatment-resistant bipolar depression (TRBD) have exhausted multiple medication regimens with limited benefit.
“Patients with bipolar depression often don’t have a lot of options. Our study is the largest to date reporting safety outcomes on a sample of real-world patients with bipolar depression treated with ketamine or esketamine.”
— Dr. Samuel T. Wilkinson, Yale Psychiatry, 2024
What the Research Shows
A landmark study from Yale Psychiatric Hospital (Wilkinson et al., published in the Journal of Clinical Psychiatry, 2024) followed 45 patients with treatment-refractory bipolar depression treated with IV ketamine or intranasal esketamine over nearly a decade. Key findings:
- 39% of patients achieved clinical response (≥50% reduction in depression severity)
- 13% achieved remission
- Mean depression scores decreased by 38.3% following the acute treatment series
- No patients experienced mania or hypomania during the acute treatment phase (when infusions were given twice weekly)
- The median time from first treatment to any manic/hypomanic event was 266 days — far exceeding the typical 95-day treatment period, suggesting the treatments themselves did not substantially increase risk
39%
Clinical response rate in Yale real-world bipolar depression cohort (ketamine/esketamine)
0
Patients experienced mania or hypomania during the acute treatment phase in the Yale study
Hours
Timeframe for onset of antidepressant effects — versus weeks or months with standard bipolar treatments
A 2023 scoping review in Healthcare summarized 10 clinical studies and concluded that IV ketamine shows preliminary evidence of efficacy, tolerability, and safety in bipolar depression — and, importantly, that it did not appear to carry a higher rate of manic induction compared to patients with major depressive disorder when administered with concurrent mood-stabilizing medications.
A separate retrospective study of 59 patients with treatment-resistant bipolar depression found significant improvement in depression severity from the second week of treatment onward, with no ketamine-induced manic switch observed during the study period, and improvements in specific PTSD-relevant items including internal tension, sleep, and suicidal ideation.
Our Approach to Bipolar Depression Care
We treat bipolar depression with particular attention to safety and coordination. Before beginning treatment, we review your full psychiatric history, current mood-stabilizing regimen, and most recent psychiatric evaluation. We believe ketamine should be used as an adjunct to — not a replacement for — ongoing psychiatric care and mood stabilization.
Key elements of our bipolar protocol
• Thorough evaluation of bipolar subtype, current episode status, and medication regimen before initiating treatment
• Confirmation of adequate mood stabilizer coverage prior to ketamine treatment
• Close monitoring for any hypomanic or manic symptoms throughout the course
• Active communication with your treating psychiatrist
• Conservative approach to maintenance — more frequent monitoring during the transition from acute to maintenance phases
Who we treat in this category: Adults with Bipolar I or Bipolar II disorder currently in a depressive episode, particularly those with treatment-resistant bipolar depression who are on adequate mood stabilization and whose psychiatrist supports evaluation for ketamine therapy.